TipRanks
Go Ultimate55% OFF

Covestro (1COVN) AI Stock Analysis

MX:1COVN

Covestro

(BMV:1COVN)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Moderate LeverageThe sizeable equity base relative to debt provides a financial cushion through the chemicals cycle. Manageable leverage should preserve access to funding and support continued operations while management works to restore profitability.
Negative Factors
Declining RevenueSustained revenue contraction indicates weak volumes, pricing, or mix rather than a brief quarterly fluctuation. Prolonged weakness can reduce plant utilization and operating leverage, making a durable recovery dependent on industrial demand and improved market conditions.

Covestro (1COVN) vs. SPDR S&P 500 ETF (SPY)

-10%-5%0%5%10%15%20%MX:1COVN-5.64%SPY+12.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
MXN 12.56B
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-23.8
Beta (1Y)
0.09
Revenue Growth
0.03%
EPS Growth
-153.83%
Country
Mexico
Employees
17,598
Sector
Basic Materials
Sector Strength
61
Industry
Chemicals - Specialty

Covestro Business Overview & Revenue Model

Company Description

Covestro AG operates as a supplier of polymer materials and application solutions. The company operates in two segments, Performance Materials, and Solutions & Specialties. The Performance Materials segment develops, produces, and supplies high-perfo...

Covestro Earnings Call Summary

Earnings Call Date:Oct 29, 2025(Q3-2025)|% Change Since:-0.67%|Next Earnings Date:May 04, 2026
Earnings Call SentimentNegative

The quarter shows clear operational and market challenges: a sizable sales decline (-12% YoY), EBITDA pressures (-15.7% YoY) and a material guidance downgrade to EUR 700–800 million for FY2025 driven by pricing, FX and the Dormagen incident (estimated up to EUR 150m). Offsets include successful cost-savings that supported Q3 EBITDA, a positive Q3 free operating cash flow (EUR 111m), a EUR 75m insurance reimbursement, strategic acquisitions to expand aliphatics capacity, and maintained credit metrics with Moody's confirming an investment-grade rating. Overall, the negative financial trends and the significant guidance reduction outweigh the mitigating positives.

Positive Updates

Strategic Acquisitions and Capacity Expansion
Completed purchase of Pontacol in Q3 2025 and signed agreement to acquire 2 HDI derivative production facilities from Vencorex (Rayong, Thailand and Freeport, U.S.) expected to close in Q1 2026. Deal expands aliphatics footprint in U.S. and APAC, expected to add a low double-digit million euro EBITDA and deliver synergies of up to high double-digit million euros within five years.

Negative Updates

Significant Sales Decline
Q3 2025 sales fell 12% year-over-year to EUR 3.2 billion. The sales decrease was driven primarily by negative pricing (-7 percentage points), adverse foreign exchange impacts (-3.5 percentage points), and lower volumes (-1.5 percentage points).

Company Guidance

Covestro narrowed its FY2025 guidance, now targeting EBITDA of EUR 700–800 million (midpoint EUR 750m, down from a Feb midpoint of EUR 1.3bn and a July midpoint of EUR 900m), free operating cash flow of -EUR 400 to -EUR 200 million (9M FOCF -EUR 370m; Q3 FOCF +EUR 111m), and sales around EUR 13.0 billion (Q3 sales EUR 3.2bn); CapEx remains guided at EUR 700–800m (9M CapEx EUR 556m), ROCE above WACC is forecast at -9 to -8 percentage points, greenhouse gas emissions are narrowed to 4.2–4.4 million tonnes, total net debt rose EUR 292m vs end‑2024 with a net‑debt/EBITDA of 3.8x (4‑quarter rolling EBITDA EUR 0.8bn), and the Dormagen incident is expected to burden FY EBITDA by up to EUR 150m (EUR 75m insurance payment received, EUR 25m deductible, coverage expected above EUR 100m); management also flagged pulling forward low‑ to mid‑double‑digit million euro restructuring costs into 2025 as a mitigation measure.

Covestro Peers Comparison

Overall Rating

Financial Indicators

MX:1COVN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$10.43B7.12-0.05%2.87%2.86%-36.73%

* Basic Materials Sector Average

Performance Comparison

0%2%4%MX:1COVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MX:1COVN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MX:1COVNCovestro AG754.90-5.10-0.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.